Apollo's needle-free insulin study nets 80% success rate

By Elaine Rigoli

Tampa, Fla., Sept. 25 - Apollo Life Sciences said Monday that it achieved a major breakthrough - making needle-free insulin for diabetes treatment now possible - by successfully lowering blood glucose levels in diabetic rats with oral insulin, using its proprietary oral-delivery technology, Oradel.

The Sydney, Australia, biotechnology company said oral feeding of diabetic rats with Oradel insulin resulted in reduction in blood glucose levels in responder animals of up to 80%, which persisted for longer than six hours.

In these studies, the oral insulin formulation was administered once daily to diabetic rats, and blood glucose levels were measured at one- or two-hour intervals over an extended period.

The company said the current treatment for diabetics requires up to 1,500 insulin injections a year to manage their condition.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.